巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Soligenix

    SNGX
    0.520
    0.030
    6.17%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Soligenix - 延遲價格・最後更新於 20/05 12:15
    最高位
    0.545
    最低位
    0.520
    開市價
    --
    前收市價
    0.490
    成交量(千)
    0.35
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    22.34
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    1.340 - 0.380
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Soligenix
    證券代碼
    SNGX.US
    所屬板塊
    Biotechnology
    公司業務
    Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
    發行量
    40020461
    公司總部
    29 Emmons Drive, Suite B-10
    公司網址
    https://www.soligenix.com
    公司電郵
    emyrian@dorbiopharma.com
    公司電話
    +1 609 538-8200
    暫無內容

    關於

    Soligenix(SNGX.US)所屬的行業板塊為Biotechnology。
    Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
    詳細公司背景可參考: https://www.soligenix.com